Rhainds, David
Brodeur, Mathieu R.
Tardif, Jean-Claude
Article History
Accepted: 3 May 2021
First Online: 8 July 2021
Declaration
:
: David Rhainds and Mathieu R. Brodeur declare that they have no conflict of interest.Jean-Claude Tardif reports grants from Amarin, Esperion, Ionis, and Pfizer and grants and personal fees from AstraZeneca, Sanofi, and Servier; grants, personal fees, and other from Dalcor; and personal fees from HLS Therapeutics, outside the submitted work. In addition, Dr. Tardif has a patent on Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent pending (US20170233812A1) and a patent on Methods for using low dose colchicine after myocardial infarction with the invention assigned to the Montreal Heart Institute (US Provisional Applications No.62/935,751 and 62/935,865).
: This article does not contain any studies with human or animal subjects performed by any of the authors.